Gravesteijn, Gido http://orcid.org/0000-0002-2610-8728
Munting, Leon P. http://orcid.org/0000-0002-2352-4451
Overzier, Maurice http://orcid.org/0000-0002-8143-4884
Mulder, Aat A. http://orcid.org/0000-0002-4779-099X
Hegeman, Ingrid
Derieppe, Marc http://orcid.org/0000-0002-9099-1746
Koster, Abraham J. http://orcid.org/0000-0003-1717-2549
van Duinen, Sjoerd G. http://orcid.org/0000-0003-4682-8869
Meijer, Onno C. http://orcid.org/0000-0002-8394-6859
Aartsma-Rus, Annemieke http://orcid.org/0000-0003-1565-654X
van der Weerd, Louise http://orcid.org/0000-0002-5997-2125
Jost, Carolina R. http://orcid.org/0000-0001-8342-1094
van den Maagdenberg, Arn M. J. M. http://orcid.org/0000-0002-9310-5535
Rutten, Julie W. http://orcid.org/0000-0003-3250-7263
Lesnik Oberstein, Saskia A. J. http://orcid.org/0000-0002-1268-8995
Funding for this research was provided by:
Hersenstichting (HA2016-02-03)
Article History
Received: 19 March 2019
Revised: 12 August 2019
Accepted: 23 September 2019
First Online: 30 October 2019
Compliance with Ethical Standards
:
: All applicable international, national and/or institutional guidelines for the care and use of animals were followed. Experiments were approved by the local animal ethics committee (code 14073) and conducted in accordance with recommendations of the European Communities Council Directive (2010/63/EU) and ARRIVE guidelines. All efforts were made to minimize animal suffering. Except from using post-mortem material, this article does not contain any studies with human participants performed by any of the authors.
: GG, JWR and SAJLO were supported by the Netherlands Brain Foundation (HA2016-02-03). SAJLO is co-inventor on an LUMC owned patent, not related to this work. LPM and LvdW were supported by NWO-VIDI (864.13.014). MO, AAM, IH, MD, AJK, SGvD, OCM, CRJ and AMJMvdM have nothing to disclose. AAR has nothing to disclose related to this work. For full transparency, she discloses being employed by LUMC and being co-inventor on several LUMC owned patents. As such she is entitled to a share of royalties. AAR further discloses being ad hoc consultant for PTC Therapeutics, BioMarin Pharmaceuticals Inc., Global Guidepoint, GLG consultancy, Grunenthal, Eisai, Sarepta Therapeutics and BioClinica, and having been a member of the Duchenne Network Steering Committee (BioMarin) and of the scientific advisory boards of ProQR and Philae Pharmaceuticals. Remuneration for these activities is paid to LUMC. LUMC also received speaker honoraria from PTC Therapeutics and BioMarin Pharmaceuticals.